|
|
||||||||
Departments of 1Pharmacology and 2Anatomy and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
Submitted 11 April 2005 ; accepted in final form 29 April 2005
In the vascular system, endothelin (ET) type B (ETB) receptors for ET-1 are located on endothelial and on venous and arterial smooth muscle cells. In the present study, we investigated the hemodynamic effects of chronic ETB receptor blockade at low and high doses in the Syrian Golden hamster. After 16 days of gavage with A-192621 (0.5 or 30 mg·kg1·day1), a selective ETB receptor antagonist, hamsters were anesthetized with a mixture of ketamine and xylazine (87 and 13 mg/kg im, respectively), and basal mean arterial blood pressure (MAP) and pressor responses to exogenous ET-1 were evaluated. The lower dose of A-192621 (0.5 mg·kg1·day1) did not modify basal MAP, whereas the higher dose (30 mg·kg1·day1) increased MAP and plasma ET levels. Radio-telemetry recordings confirmed the increase in MAP induced by the higher dose of A-192621 in conscious hamsters. On the other hand, although the lower dose of A-192621 was devoid of intrinsic pressor effects, it markedly reduced the transient hypotensive phase induced by intravenously injected IRL-1620, a selective ETB receptor agonist. Finally, A-192621 (0.5 mg·kg1·day1) alone or A-192621 (30 mg·kg1·day1) + atrasentan (6 mg·kg1·day1), a selective ETA receptor antagonist, potentiated the pressor response to exogenous ET-1. Our results suggest that, in the hamster, ETB receptors on vascular smooth muscle cells are importantly involved in the clearance of endogenous ET-1, whereas the same receptor type on the endothelium is solely involved in the vasodilatory responses to the pressor peptide. Blockade of endothelial and vascular smooth muscle cell ETB receptors triggers a marked potentiation of ETA-dependent increases in systemic resistance.
clearance; telemetry
This article has been cited by other articles:
![]() |
K. Sachidanandam, M. M. Elgebaly, A. K. Harris, J. R. Hutchinson, E. M. Mezzetti, V. Portik-Dobos, and A. Ergul Effect of chronic and selective endothelin receptor antagonism on microvascular function in Type 2 diabetes Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2743 - H2749. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Linder, J. Diaz, W. Ni, T. Szasz, R. Burnett, and S. W. Watts Vascular reactivity, 5-HT uptake, and blood pressure in the serotonin transporter knockout rat Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1745 - H1752. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Abassi, B. Bishara, T. Karram, S. Khatib, J. Winaver, and A. Hoffman Adverse effects of pneumoperitoneum on renal function: involvement of the endothelin and nitric oxide systems Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R842 - R850. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Fink, M. Li, Y. Lau, J. Osborn, and S. Watts Chronic Activation of Endothelin B Receptors: New Model of Experimental Hypertension Hypertension, September 1, 2007; 50(3): 512 - 518. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |